11. Assay Procedure Continued...

Manual Wash Procedure
Empty the wells by inversion. Using a multi-channel pipette or wash bottle, fill the wells with wash buffer. Empty by inversion and blot the wells on absorbent paper. Repeat this wash process 2 more times.

6. Dispense 100µl of Conjugate (Reagent 3) into each well. Incubate the wells for 30 minutes at room temperature.

7. After 30 minutes, discard the well contents and carefully wash the wells 4 times with Wash Buffer. Ensure that the wells are empty but do not allow to dry out.

8. Using a repeating dispenser, rapidly dispense 100µl of TMB Substrate (Reagent 4) into each well. Incubate the plate for 10 minutes.

9. Add 100µl of Stop Solution (Reagent 5) to each well. To allow equal reaction times, the Stop Solution should be added to the wells in the same order as the TMB Substrate.

10. Read the optical density (OD) of each well at 450nm in a microplate reader within 10 minutes. A 640nm filter may be used as a reference wavelength.

12. Quality Control
Quality control data is supplied on the lot-specific QC certificate included in the kit. Controls are intended to monitor for substantial reagent failure.

Any well positive by spectrophotometer but without visible colour should be cleaned on the underside and re-read. If OD-values below zero are observed, the wavelengths used should be verified, the reader re-blanked to air and the measurements repeated.

13. Interpretation of Results

Quantitative Results
Plot the OD of each standard against its concentration and draw the best-fit curve through the points. Read the unknowns off this curve. In-house data indicate that citrullinated protein IgG activity above 6.25 U/ml is characteristic of RA. Samples with values greater than 100 U/ml should be re-assayed at a higher dilution e.g. 1:600.

Qualitative Results
Samples with OD > OD of 6.25 U/ml standard are positive
Samples with OD < OD of 6.25 U/ml standard are negative

14. Limitations of the Procedure
For diagnostic purposes, Citrullinated Peptide IgG ELISA results should be used in conjunction with other test results and overall clinical presentation.

15. Performance Characteristics
Clinical sensitivity for the assay was determined using samples from 140 clinically confirmed RA patients. Clinical specificity was calculated from data obtained using 122 samples from non-RA patients with a variety of autoimmune conditions.

Clinical specificity: 100%
Clinical sensitivity: 80%

16. Reproducibility

Within Assay Precision

<table>
<thead>
<tr>
<th>Mean U/ml</th>
<th>n</th>
<th>SD</th>
<th>CV%</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.25</td>
<td>8</td>
<td>0.26</td>
<td>4.3</td>
</tr>
<tr>
<td>12.5</td>
<td>8</td>
<td>0.87</td>
<td>3.7</td>
</tr>
<tr>
<td>50</td>
<td>8</td>
<td>1.95</td>
<td>4.3</td>
</tr>
</tbody>
</table>

Between Assay Precision

CV%: <12%

17. Method Summary

- Dilute sera 1:100 with Sample Diluent (Reagent 1)
- Dispense 100 µl of the Standard(s), the Positive and Negative Controls and the diluted sample into the microplate wells
- Incubate for 30 minutes at room temperature.
- Wash the wells three times
- Dispense 100µl of Conjugate (Reagent 3) into each well
- Incubate at room temperature for 30 minutes
- Wash the wells four times
- Add 100µl of TMB Substrate (Reagent 4) to each well
- Incubate at room temperature for 10 minutes
- Add 100µl Stop Solution (Reagent 5) to each well
- Read the optical density at 450nm (single wavelength) or 450/620nm (dual wavelength)

18. Further Reading


1. Materials Included in the Kit
- Microplate: 96 wells in 12 X 8 break-apart strips, pre-coated with recombinant citrullinated rat filagrin, with holder in a foil bag with desiccant
- Reagent 1: Sample Diluent 150mM Tris-buffered saline, pH 7.2 with antimicrobial agent, 10ml, (blue), concentrate (x15)
- Reagent 2: Wash Buffer 100mM Tris-buffered saline with detergent, pH 7.2, concentrate, 100ml, concentrate (x10)
- Reagent 3: Conjugate rabbit anti-human IgG conjugated to horseradish peroxidase in protein stabilising solution and antimicrobial agent, 12 ml, (red), ready to use
- Reagent 4: TMB Substrate aqueous solution of TMB and hydrogen peroxide, 12 ml, ready to use
- Reagent 5: Stop Solution 0.25M sulphuric acid, 12 ml, ready to use
- Standards: 0, 6.25, 12.5, 25, 50 & 100 U/ml, 1ml of 10mM Tris-buffered saline containing human serum IgG antibodies to citrullinated protein, ready to use
- Positive Control: 1ml of 10mM Tris-buffered saline containing human serum antibodies to citrullinated protein, ready to use
- Negative Control: 1ml of 10mM Tris-buffered saline containing normal human serum, ready to use
- Instructions for use
2. Other Equipment Required

Test tubes for dilution • graduated cylinder for preparing wash buffer • precision pipettes and disposable tips to deliver 15μl, 100μl, 1ml • EIA microplate washer or multi-channel pipette or wash bottle • distilled or deionised water • absorbent paper • EIA microplate reader with 450nm and optional 620nm reference filter. Alternatively, a suitable, self-validated automated system may be used.

Instrumentation, whether manual or automated, should meet the following criteria: pipettes with better than 3% imprecision with no carry over between pipetting steps; microplate washers should remove 99% of fluid; automated machines should minimise time between washing and adding the next reagent.

3. Intended Use

The Citrullinated Protein Antibodies kit is a rapid ELISA method for the detection of rheumatoid arthritis specific IgG antibodies to citrullinated protein. The components of the kit are for in vitro diagnostic use only.

4. Explanation of the Test

Rheumatoid arthritis (RA) is diagnosed primarily on clinical disease manifestations, and serological supporting evidence has, until recently, been restricted to the determination of rheumatoid factor. However, this antibody occurs in many inflammatory diseases and in healthy, elderly individuals.

Recently, citrullinated protein antibodies (CPA) have been shown to be highly specific for RA. (1, 2). The antigenic determinants recognised by these antibodies contain a modified form of arginine, termed citrulline, involved in a peptidylarginine deiminase (3).

Citrullination has been shown to be an essential step in generating RA-specific antibodies in susceptible individuals, perhaps via a breakdown in immune tolerance to self-antigens. Importantly, citrullinated fibrin has been identified in rheumatoid synovial membranes (4). Citrullinated protein is also present in perinuclear granules of buccal mucosa and is associated with keratin fibrils in the stratum corneum of the esophagus. Recent studies have shown the citrullinated protein to be filaggrin and the target recognised by anti-perinuclear factor antibodies and the anti-keratin antibodies.

Importantly, CPA can be detected both in early and fully developed RA and are even present in some patients several years prior to the onset of disease. The ability to accurately diagnose RA in the early stages of the disease, or even before disease onset, obviously allows for earlier treatment and the opportunity to delay disease progression.

The CPA ELISA uses citrullinated recombinant rat filaggrin as the antigen for the detection of anti-citrullinated protein antibodies because it has been shown to be a more effective substrate than human proteins. The resulting CPA test is highly specific and sensitive for the detection of RA.

5. Principle of the Test

Diluted serum samples are incubated with recombinant citrullinated rat filaggrin immobilised on microtitre wells. After washing away unbound serum components, rabbit anti-human IgG conjugated to horseradish peroxidase is added to the wells and this binds to surface-bound antibodies in the second incubation. Unbound conjugate is removed by washing, and a solution containing 3,3’,5,5’-tetramethylbenzidine (TMB) and enzyme substrate is added to trace specific antibody binding. Addition of Stop Solution terminates the reaction and provides the appropriate pH for colour development. The optical densities of the standard(s), controls and samples are measured using a microplate reader at 450nm.

6. Safety Precautions

1. All reagents in this kit are for in vitro diagnostic use only.
2. Only experienced laboratory personnel should use this test. The test protocol must be followed strictly.
3. CAUTION: the device contains material of human and animal origin and should be handled as a potential transmitter of diseases. All human source material used in the preparation of standards and control for this product have been tested and found negative by ELISA for antibodies to HIV, HbsAg and HCV. No test method, however, can offer complete assurance that infectious agents are absent. Therefore, all reagents containing human material should be handled as if potentially infectious. Operators should wear gloves and protective clothing when handling any patient sera or serum based products.
4. Reagents of this kit contain antimicrobial agents and the Substrate solution contains 3,3’,5,5’-tetramethylbenzidine. Avoid contact with the skin and eyes. Rinse immediately with plenty of water if any contact occurs.
5. The Stop Solution contains 0.25M sulphuric acid. Avoid contact with skin and eyes. Rinse immediately with plenty of water if contact occurs.
6. Any liquid that has been brought into contact with potentially infectious material has to be discarded in a container with a disinfectant. Dispose of plates and specimens as clinical waste. Any unused reagents should be flushed away with copious amounts of water. Disposal must be performed in accordance with local legislation.

7. Technical Precautions

1. Strips and solutions should not be used if the foil bag is damaged or liquids have leaked.
2. Allow all reagents and the microplate to reach room temperature before use. Ensure that the microplate foil bag containing any unused strips is well sealed and contains the desiccant to avoid moisture. Store at 2 - 8°C after use.
3. The sample diluted X15 concentrate contains 0.09% sodium azide as preservative. Prepare sufficient working strength diluent for the assay run. However, if the working strength diluent is to be stored for more than 1 week, add sodium azide (0.9g/L). Store unused sample diluent concentrate and dilute sample diluent at 2 - 8°C.
4. Include the positive and negative control in every test run to monitor for reagent stability and correct assay performance.
5. Strictly observe the indicated incubation times and temperature.
6. When automating, consider excess volumes required for setting up the instrument and dead volume of robot pipette
7. Ensure that no cross-contamination occurs between wells. Keep all pipettes and other equipment used for enzyme conjugate completely separate from the substrate reactant.
8. When pipetting Conjugate or Substrate, aliquots for the required numbers of wells should be taken to avoid multiple entry of pipette tips into the reagent bottles. Never pour unused reagents back into the original bottles.
9. Do not allow microwells to dry between incubation steps.

10. Strictly follow the described wash procedure. Insufficient washing may cause high background signal.
11. Avoid direct sunlight and exposure to heat sources during all incubation steps.
12. Replace colour-coded caps on their correct vials to avoid cross-contamination
13. It is important to dispense all samples and controls into the wells without delay. Therefore ensure that all samples are ready to dispense.

8. Shelf Life and Storage Conditions

On arrival, store the kit at 2 - 8°C. Once opened the kit is stable for 3 months (or until its expiry date if less than 3 months). Do not use kits beyond their expiry date. Do not freeze any kit component. The diluted Wash Buffer and Sample Diluent (see Technical Precautions) have a shelf life of 3 months if stored in a closed bottle at 2 - 8°C.

9. Specimen Collection and Storage

Serum or plasma samples may be used and should be stored at -20°C for long-term storage. Frozen samples must be mixed well after thawing and prior to testing. Repeated freezing and thawing can affect results. Addition of preservatives to the serum sample may adversely affect the results. Microbiologically contaminated, heat-treated or specimens containing particulate matter should not be used. Grossly haemolysed, icteric or lipaemic specimens should be avoided.

10. Preparation of Reagents

1. Dilute the Sample Diluent (Reagent 1) 1:14 in distilled water to make sufficient buffer for the assay run.
2. Dilute the Wash Buffer (Reagent 2) 1:9 in distilled water to make sufficient buffer for the assay run e.g. add 50ml wash buffer concentrate to 450ml water.

11. Assay Procedure

1. Dilute patient samples 1:100 in diluted Sample Diluent (e.g. 10μl serum plus 1ml diluent).
2. Assemble the number of strips required for the assay.
3. For quantitative assays, dispense 100 μl of each Standard, the Negative and Positive Controls and the diluted patient samples into appropriate wells. For qualitative assays, dispense 300 μl of the 6.25 U/ml Standard, the controls and diluted samples.
4. Incubate for 30 minutes at room temperature.
5. After 30 minutes, decant or aspirate the well contents and wash the wells 3 times using automated washing or the manual wash procedure (see below).

Careful washing is the key to good results. Do not allow the wells to dry out.